Inclusion Criteria:

- HLA-A*0201 positive adults over the age of 18.

- Have HCC with a serum AFP determination >30ng/ml.

- Both male and female patients may be enrolled.

- Karnofsky Performance Status greater than or equal to 70 percent.

- No previous evidence of class 3 or greater New York Heart Association cardiac
insufficiency or coronary artery disease.

- No previous evidence of opportunistic infection.

- Adequate baseline hematological function as assessed by the following laboratory
values with 30 days prior to study entry:

1. Hemoglobin >9.0g/dl

2. Platelets >50000/mm3

3. Absolute Neutrophil Count >1,000/mm3

- Child-Pugh Class A or B for chronic liver disease.

- Ability to give informed consent.

Exclusion Criteria:

- Any congenital or acquired condition leading to inability to generate an immune
response, including concomitant immune suppressive therapy.

- Concomitant steroid therapy or chemotherapy, or any of these other treatments < 30
days before the first vaccination.

- Females of child-bearing potential must have negative serum beta-HCG pregnancy test
(within Day -14 to Day 0).

- Acute infection: any acute viral, bacterial, or fungal infection, which requires
specific therapy. Acute therapy must have been completed within 14 days prior to
study treatment.

- HIV-infected patients.

- Patients with any underlying conditions which would contraindicate therapy with study
treatment.

- Patients with organ allografts.

- O2 sat <91% on room air; dyspnea at rest.